| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 95,287 | 81,948 | ||
| Short-term investments | 454,378 | 548,780 | ||
| Receivable from contracts with collaborators | 35,936 | 4,574 | ||
| Prepaid expenses and other current assets | 35,062 | 24,773 | ||
| Total current assets | 620,663 | 660,075 | ||
| Property and equipment, gross | 11,265 | - | ||
| Less accumulated depreciation | 3,868 | - | ||
| Property and equipment, net | 7,397 | 3,912 | ||
| Operating lease right-of-use assets | 7,539 | 7,864 | ||
| Other long-term assets | 13,782 | 10,574 | ||
| Total assets | 649,381 | 682,425 | ||
| Accounts payable and accrued expenses | 66,788 | 52,931 | ||
| Current operating lease liabilities | 1,429 | 1,696 | ||
| Current portion of long-term debt | 4,337 | 3,112 | ||
| Current portion of contract liabilities | 48,750 | 49,435 | ||
| Total current liabilities | 121,304 | 107,174 | ||
| Long-term debt, net of current portion | 5,336 | 6,509 | ||
| Long-term operating lease liabilities | 8,364 | 8,156 | ||
| Other long-term liabilities | 2,981 | 2,595 | ||
| Long-term contract liabilities | 268,854 | 252,505 | ||
| Total liabilities | 406,839 | 376,939 | ||
| Common stock, 0.0001 par value 200,000 shares authorized 87,016 and 78,229 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 9 | 9 | ||
| Additional paid-in capital | 1,334,704 | 1,323,739 | ||
| Accumulated other comprehensive income | 918 | 711 | ||
| Accumulated deficit | -1,093,089 | -1,018,973 | ||
| Total stockholders' equity | 242,542 | 305,486 | ||
| Total liabilities and stockholders' equity | 649,381 | 682,425 | ||
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)